Nerison C may be available in the countries listed below.
Ingredient matches for Nerison C
Chlorquinaldol is reported as an ingredient of Nerison C in the following countries:
- New Zealand
International Drug Name Search
Nerison C may be available in the countries listed below.
Chlorquinaldol is reported as an ingredient of Nerison C in the following countries:
International Drug Name Search
Lafunomyl may be available in the countries listed below.
Alfuzosin hydrochloride (a derivative of Alfuzosin) is reported as an ingredient of Lafunomyl in the following countries:
International Drug Name Search
Duoflu may be available in the countries listed below.
Fluocinolone Acetonide is reported as an ingredient of Duoflu in the following countries:
International Drug Name Search
Fraxiparin may be available in the countries listed below.
Nadroparin Calcium is reported as an ingredient of Fraxiparin in the following countries:
International Drug Name Search
Ciprofloxacin Alvia may be available in the countries listed below.
Ciprofloxacin lactate (a derivative of Ciprofloxacin) is reported as an ingredient of Ciprofloxacin Alvia in the following countries:
International Drug Name Search
Generic Name: cyanocobalamin (oral) (sye AN oh koe BAL a min)
Brand Names: B-12 Resin, Vitamin B-12, Vitamin B12
Cyanocobalamin is a man-made form of vitamin B12. Vitamin B12 is important for growth, cell reproduction, blood formation, and protein and tissue synthesis.
Cyanocobalamin is used to treat vitamin B12 deficiency in people with pernicious anemia and other conditions.
Cyanocobalamin may also be used for purposes other than those listed in this medication guide.
To treat pernicious anemia, you will have to use this medication on a regular basis for the rest of your life. Not using the medication can lead to irreversible nerve damage in your spinal cord.
Pernicious anemia is also treated with folic acid to help maintain red blood cells. However, folic acid will not treat Vitamin B12 deficiency and will not prevent possible damage to the spinal cord. Take all of your medications as directed.
If you have any of these other conditions, you may need a dose adjustment or special tests to safely take oral cyanocobalamin:
any type of infection;
iron or folic acid deficiency;
kidney or liver disease; or
if you are receiving any medication or treatment that affects bone marrow.
Use this medication exactly as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended. Follow the directions on your prescription label.
The sublingual tablet should be placed under your tongue where it will dissolve.
To be sure this medication is helping your condition, your blood will need to be tested every 3 to 6 months. This will help your doctor determine the correct dose and how long to treat you with cyanocobalamin. Do not miss any scheduled appointments.
To treat pernicious anemia, you will have to use this medication on a regular basis for the rest of your life. Not using the medication can lead to irreversible nerve damage in your spinal cord.
Pernicious anemia is also treated with folic acid to help maintain red blood cells. However, folic acid will not treat Vitamin B12 deficiency and will not prevent possible damage to the spinal cord. Take all of your medications as directed.
Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.
chest pain;
feeling short of breath, even with mild exertion;
swelling, rapid weight gain; or
unusual warmth, redness, or pain in an arm or leg.
Less serious side effects may include:
headache, dizziness, weakness;
nausea, upset stomach, diarrhea;
numbness or tingling;
fever;
joint pain;
swollen tongue;
swelling; or
itching or rash.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking cyanocobalamin, tell your doctor if you are taking any of the following medications:
antibiotics;
methotrexate (Rheumatrex);
pyrimethamine (Daraprim);
colchicine; or
if you drank a lot of alcohol within the past 2 weeks.
This list is not complete and there may be other drugs that can interact with cyanocobalamin. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
See also: B-12 Resin side effects (in more detail)
Class: Antibacterials
VA Class: DE101
CAS Number: 1405-87-4
Brands: AK-Poly-Bac
Antibacterial; polypeptide antibiotic produced by Bacillus subtilis.104 a d e f
Treatment of superficial infections of the eye involving the conjunctiva and/or cornea caused by susceptible organisms.101 d e
Used alone or in fixed combination with other topical anti-infectives (e.g., neomycin, polymyxin B) with or without topical corticosteroids (e.g., hydrocortisone) when such combination therapy is indicated.104 a d e f (See Use of Fixed Combinations under Cautions.)
Not recommended for topical prophylaxis of neonatal ophthalmia.a
Not indicated for treatment of deep-seated ocular infections or infections likely to become systemic.101
Apply topically to conjunctival sac of the eye as an ointment.101
Not for injection into the eye; do not instill directly into the anterior chamber of the eye.104 e f
When treating blepharitis, carefully remove all scales and crusts prior to application of the ointment; spread ointment uniformly over lid margins.101
Avoid contaminating the tip of the ointment container.101 104 e f
Available as bacitracin alone; as fixed combination containing bacitracin zinc and polymyxin B sulfate; and as fixed combinations containing bacitracin zinc, and neomycin and polymyxin B sulfates, with or without hydrocortisone or hydrocortisone acetate. Dosage of bacitracin or bacitracin zinc is expressed in terms of bacitracin.101 104 d e f
Apply into the conjunctival sac of the affected eye(s) 1–3 times daily.101
Apply to affected eye(s) every 3 or 4 hours for 7–10 days, depending on the severity of the infection.e
Apply to affected eye(s) every 3 or 4 hours, depending on severity of the condition.104 f
Apply to affected eye(s) every 3 or 4 hours for 7–10 days, depending on the severity of the infection.d
No special population dosing recommendations at this time.101 104 a d e f
Known hypersensitivity to bacitracin or any ingredient in the formulation.101 104 a d e f
Cutaneous sensitization possible (e.g., itching, reddening, conjunctival or eyelid edema).104 e
Hypersensitivity reactions (e.g., itching, rash, swelling of lips and face, sweating, tightness of the chest), including anaphylaxis, reported rarely.a
During long-term use of topical antibiotics, periodically examine patient for signs of sensitization; may manifest as a failure to heal.104 e f If signs or symptoms of sensitivity occur, discontinue the drug.101 104 a e f
Patients sensitive to neomycin may also be sensitive to bacitracin.a
Do not use for treatment of deep-seated ocular infections or infections likely to become systemic.101
Prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.101 104 d e f Discontinue drug and institute appropriate therapy if superinfection occurs.101 a d e
Ophthalmic ointments may delay healing.104 d e f
Concomitant topical corticosteroids may mask clinical signs of bacterial, fungal, or viral infections, prevent recognition of ineffectiveness of the antibiotic, or may suppress hypersensitivity reactions to bacitracin or other ingredients in the formulation.f
When bacitracin is used in fixed combination with other agents (corticosteroids, other anti-infectives), consider the cautions, precautions, and contraindications associated with the concomitant agent(s).104 d e f
Category C.104 e f
Experts consider topical bacitracin compatible with nursing.g
Use the fixed combination with neomycin and polymyxin B sulfates with caution in nursing women.e
Safety and efficacy not established in pediatric patients.104 e f
No substantial differences in safety or efficacy relative to younger patients.104 e
Not substantially absorbed from intact or denuded skin, wounds, or mucous membranes.a
Not known whether topical bacitracin is distributed into breast milk.e g
Bacitracin: 15–30°C.a
Bacitracin zinc and polymyxin B sulfate: 20–25°C.d
Neomycin and polymyxin B sulfates and bacitracin zinc: 20–25°C.e
Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone: 15–30°C.f
Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate: 15–25°C.104
Bacitracin consists of 3 separate compounds, bacitracin A, B, and C; bacitracin A is the chief constituent.a d e
May be bactericidal or bacteriostatic in action, depending on concentration of the drug attained at the site of infection and the susceptibility of the infecting organism.a e
Inhibits bacterial cell wall synthesis by preventing incorporation of amino acids and nucleotides into the cell wall.a e
Spectrum of activity includes many gram-positive aerobic bacteria, some aerobic gram-negative bacteria, and some anaerobic bacteria.a 101 e Inactive against fungi.101
Gram-positive bacteria: Active against Staphylococcus aureus and some streptococci.a 101
An increasing number of staphylococci, including penicillin-resistant staphylococci, are resistant to bacitracin.a Cross-resistance does not usually occur between bacitracin and other anti-infectives.a
Importance of not touching tip of container to the eye, eyelid, fingers, or any other surface to avoid contamination.101 104 e f Advise patient to keep container tightly closed when not in use.e f
Importance of discontinuing therapy and contacting clinician if the infection worsens or does not improve, or if any signs of sensitivity occur (e.g., rash, itching, swelling, redness, burning).101 104 a e f
Advise patient not to share the drug with any other person.104 e
Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.104 d e
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.104 e
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Ointment | 500 units/g* | Bacitracin | Akorn, Fougera |
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Ointment | Bacitracin Zinc 500 units (of bacitracin) per g and Polymyxin B Sulfate 10,000 units (of polymyxin B) per g | AK-Poly-Bac | Akorn |
Bacitracin Zinc and Polymyxin B Sulfate | Bausch & Lomb, Fougera |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Ointment | Neomycin Sulfate 0.35% (of neomycin), Polymyxin B Sulfate 10,000 units (of polymyxin B) per g, and Bacitracin Zinc 400 units (of bacitracin) per g* | Neomycin and Polymyxin B Sulfates and Bacitracin Zinc | Bausch & Lomb, Fougera |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Ointment | Neomycin Sulfate 0.35% (of neomycin), Polymyxin B Sulfate 10,000 units (of polymyxin B) per g, and Bacitracin Zinc 400 units (of bacitracin) per g, and Hydrocortisone 1%* | Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone | Bausch & Lomb |
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Ointment | Neomycin Sulfate 0.35% (of neomycin), Polymyxin B Sulfate 10,000 units (of polymyxin B) per g, Bacitracin Zinc 400 units (of bacitracin) per g, and Hydrocortisone Acetate 1% | Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Acetate | Fougera |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
Only references cited for selected revisions after 1984 are available electronically.
101. E. Fougera & Co. Bacitracin ophthalmic ointment USP prescribing information. Melville, NY; 1998 Mar.
102. Akorn. Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment USP prescribing information. Buffalo Grove, IL; 2003 Dec.
103. Akorn. Bacitracin zinc and polymyxin B sulfate ophthalmic ointment USP prescribing information. Somerset, NJ; 1998 Jul.
104. E. Fougera & Co. Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment prescribing information. Melville, NY; 2004 Aug.
a. AHFS drug information 2008. McEvoy, GK, ed. Bacitracin. Bethesda, MD: American Society of Health-System Pharmacists; 2008:2837-8.
d. Akorn, Inc. Bacitracin zinc and polymyxin B sulfate ophthalmic ointment USP prescribing information. Buffalo Grove, IL; 2007 Aug.
e. Akorn, Inc. Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment, USP prescribing information. Buffalo Grove, IL; 2007 Oct.
f. Bausch & Lomb Incorporated. Neomycin and polymyxin B sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment USP prescribing information. Tampa, FL; 2003 Nov.
g. Briggs CC, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation, 7th ed. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2005: 144-5.
h. AHFS drug information 2008. McEvoy GK, ed. EENT corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2008:2867-9.
Ambroxol Farmoz may be available in the countries listed below.
Ambroxol hydrochloride (a derivative of Ambroxol) is reported as an ingredient of Ambroxol Farmoz in the following countries:
International Drug Name Search